Starling Oncology, Inc. (STLNW) stock
STLNWNasdaqServices-Offices & Clinics of Doctors of MedicineFiscal year ends December 31Also trades as DFPH, STLN
$0.03+0.00 (+10.87%)
Close on Oct 30, 2026Market cap $665.51MP/E –Yield –
Starling Oncology total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Starling Oncology's total debt was $79.87M at Jun 30, 2026. For fiscal 2025 it was $77.40M, down 16.9% from the year before. The highest annual figure on record is $93.13M in fiscal 2024.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $77.40M | -16.9% |
| FY2024 | Dec 31, 2024 | $93.13M | +7.3% |
| FY2023 | Dec 31, 2023 | $86.83M | +7.7% |
| FY2022 | Dec 31, 2022 | $80.62M | +43955.2% |
| FY2021 | Dec 31, 2021 | $183.00K | -98.5% |
| FY2020 | Dec 31, 2020 | $11.93M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $79.87M | +6.5% |
| Q1 FY2026 | Mar 31, 2026 | $78.61M | +6.4% |
| Q4 FY2025 | Dec 31, 2025 | $77.40M | -16.9% |
| Q3 FY2025 | Sep 30, 2025 | $76.20M | -16.8% |
| Q2 FY2025 | Jun 30, 2025 | $75.02M | -16.6% |
| Q1 FY2025 | Mar 31, 2025 | $73.89M | -16.4% |
| Q4 FY2024 | Dec 31, 2024 | $93.13M | +7.3% |
| Q3 FY2024 | Sep 30, 2024 | $91.54M | +7.4% |
| Q2 FY2024 | Jun 30, 2024 | $89.95M | +7.5% |
| Q1 FY2024 | Mar 31, 2024 | $88.39M | +7.6% |
| Q4 FY2023 | Dec 31, 2023 | $86.83M | +7.7% |
| Q3 FY2023 | Sep 30, 2023 | $85.25M | +7.8% |
| Q2 FY2023 | Jun 30, 2023 | $83.69M | – |
| Q1 FY2023 | Mar 31, 2023 | $82.14M | – |
| Q4 FY2022 | Dec 31, 2022 | $80.62M | +43955.2% |
| Q3 FY2022 | Sep 30, 2022 | $79.07M | +562.8% |
| Q2 FY2022 | Jun 30, 2022 | $0 | – |
| Q1 FY2022 | Mar 31, 2022 | $0 | – |
| Q4 FY2021 | Dec 31, 2021 | $183.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $11.93M | – |